Your browser doesn't support javascript.
loading
Risk of mortality in older adults with loss of appetite: An analysis of Medicare fee-for-service data.
Dagenais, Simon; Clark, Sunday; Fielding, Roger A; Cantu, Cera; Prasad, Sapna; Dai, Feng; Groarke, John D.
Afiliação
  • Dagenais S; Pfizer, New York, NY, USA. Electronic address: simon.dagenais@pfizer.com.
  • Clark S; Pfizer, New York, NY, USA.
  • Fielding RA; Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center, Tufts University, Boston, MA, USA.
  • Cantu C; Clarify Health, San Francisco, CA, USA.
  • Prasad S; Clarify Health, San Francisco, CA, USA.
  • Dai F; Pfizer, New York, NY, USA.
  • Groarke JD; Pfizer, Cambridge, MA, USA.
J Nutr Health Aging ; 28(3): 100035, 2024 03.
Article em En | MEDLINE | ID: mdl-38308921
ABSTRACT

OBJECTIVES:

Prior research suggested that loss of appetite (LOA) among adults with Medicare fee-for-service (FFS) insurance in the United States increased the risk of mortality within 1 year; those findings were not adjusted for risk factors and confounders. The objective of this study was to compare the risk of mortality among Medicare FFS beneficiaries with LOA to a control group without LOA while controlling or adjusting for age, comorbidities, body mass index (BMI), and weight loss.

DESIGN:

Retrospective and observational analysis of Medicare FFS health insurance claims data from October 1, 2015 to December 31, 2021.

SETTING:

Claims from all settings (e.g., hospital inpatient/outpatient, office, assisted living facility, skilled nursing facility, hospice, rehabilitation facility, home) were included in these analyses.

PARTICIPANTS:

The LOA group included all individuals aged 65-115 years with continuous Medicare FFS medical coverage (Parts A and/or B) for at least 12 months before a claim with ICD-10 diagnosis code "R63.0 Anorexia". The control group was drawn from individuals aged 65-115 years with continuous Medicare FFS coverage who did not have a diagnosis of R63.0. Individuals with LOA were matched 13 to those in the control group based on age, sex, and race/ethnicity. MEASUREMENTS Mortality in the LOA group was compared to mortality in the control group using Kaplan-Meier and Cox regression analyses and stratified or adjusted in terms of Charlson Comorbidity Index (CCI), claims-based frailty index (CFI), BMI, and weight loss.

RESULTS:

The study population of 1,707,031 individuals with LOA and 5,121,093 controls without LOA was 61.7% female and 82.2% White. More individuals with LOA compared with the control group had a CCI score 5+ (52.4% vs. 19.4%), CFI score 5+ (31.6% vs. 6.4%), and BMI < 20 kg/m2 (11.2% vs. 2.1%). Median follow-up was 12 months (individuals with LOA) and 49 months (control group). In a matched population, the risk of mortality was significantly higher (unadjusted hazard ratio 4.40, 95% confidence interval 4.39-4.42) for individuals with LOA than the control group. Median survival time was 4 months (individuals with LOA) and 26 months (control group); differences in survival time remained when stratifying by CCI, BMI, and weight loss.

CONCLUSION:

Individuals with LOA had a substantially increased risk of death even after matching for age, sex, race/ethnicity, and adjusting for comorbidities. These findings highlight the burden of illness in older adults with LOA and the need for therapies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anorexia / Medicare Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anorexia / Medicare Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article